Genfit SA represents several core values and a strong corporate philosophy. The company prioritizes innovation and strives to develop groundbreaking solutions in the field of liver and metabolic diseases. Genfit SA is committed to patient-centric research and aims to improve the lives of individuals suffering from these ailments. With a focus on scientific excellence and commitment to ethical practices, Genfit SA believes in fostering collaborations and partnerships to drive progress. By combining cutting-edge research and a patient-oriented approach, Genfit SA aims to become a leading global biopharmaceutical company in its targeted therapeutic areas.

Genfit SA is primarily present in various countries and regions. The company operates not only in its home country, France, but also has a significant presence in the United States. Genfit SA also has a growing presence in other parts of the world, including Europe and Asia. This global expansion allows the company to reach a wider market and tap into diverse patient populations. With its increasing footprint, Genfit SA is well-positioned to cater to the needs of patients and healthcare providers in different countries and regions, driving its growth and success.

Genfit SA, a leading biopharmaceutical company, has achieved numerous significant milestones. Notably, the company successfully completed Phase 3 clinical trials for its investigational drug, elafibranor, in patients with nonalcoholic steatohepatitis (NASH). This milestone is remarkable as it demonstrated the drug's potential in treating a widespread liver disease with no approved therapies. Genfit SA also received Breakthrough Therapy designation from the FDA, highlighting the drug's promising efficacy and safety profile. Moreover, the company has established strong collaborations, such as the strategic alliance with LabCorp, to advance the diagnosis and treatment of NASH. Genfit SA continues to forge ahead in its mission to address significant unmet medical needs and improve patient outcomes.

Genfit SA is a renowned biopharmaceutical company based in France. Established in 1999, Genfit specializes in the development of innovative therapeutic and diagnostic solutions to address metabolic, inflammatory, and liver diseases. With a strong focus on pioneering research and advanced clinical trials, Genfit has positioned itself as a leading player in the pharmaceutical industry. The company's primary mission is to improve patient outcomes by combating diseases that represent significant medical and social challenges. Genfit SA continually strives to create value for its stakeholders through its commitment to scientific excellence, strategic collaborations, and dedication to addressing unmet medical needs.

The main competitors of Genfit SA in the market are Intercept Pharmaceuticals, Inc., Viking Therapeutics, Inc., and Madrigal Pharmaceuticals, Inc.

Genfit SA is primarily active in the pharmaceutical and biotechnology industries.

Genfit SA's business model focuses on developing and commercializing innovative therapeutic solutions for patients with metabolic and liver-related diseases. The company primarily specializes in non-alcoholic steatohepatitis (NASH), which is a progressive disease of the liver. Genfit SA's business strategy involves conducting research and development activities, clinical trials, and obtaining regulatory approvals. By creating a pipeline of potential drug candidates, Genfit SA aims to address the unmet medical needs of individuals suffering from NASH and related conditions. The company's ultimate goal is to provide effective treatment options and improve the overall quality of life for patients in this specific market.

Genfit KGV ir 8,62.

Genfit KUV ir 2,21.

AlleAktien kvalitātes vērtējums Genfit ir 5/10.

gaidāmā Genfit apgrozījums ir 88,08 milj. EUR.

gaidāmā Genfit peļņa ir 22,55 milj. EUR.

Genfit SA is a French biotech company focused on the development and commercialization of therapies for the treatment of metabolic diseases. The company is listed on the Euronext stock exchange in Paris and also has a branch in the US. Genfit SA utilizes an integrated business model that focuses on three main activities: research and development, diagnostics, and therapeutics.

Genfit izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Genfit vai uzņēmums nedod dividendes.

Genfit ISIN ir FR0004163111.

Genfit WKN ir A0LGJ2.

Genfit simbols ir GNFT.PA.

Pēdējo 12 mēnešu laikā Genfit maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Genfit plāno maksāt dividendes 0 EUR apmērā.

Genfit pašreizējā dividendu rentabilitāte ir .

Genfit maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Genfit pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Genfit tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Genfit apmērā 0 EUR, kas tika izmaksāta 1.12.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 1.12.2024..

Pēdējās dividendes izmaksa notika 1.12.2024..

Gadā 2023, Genfit izmaksāja 0 EUR dividendes.

Genfit dividendes tiek izmaksātas EUR.